Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9107125 | 0.98 | ATM (0.46) | ATMCNR1CNR2MMEOGFRL1 | |
| SCHEMBL29625942 | 0.98 | ATM (0.46) | ATMCNR1CNR2MMEOGFRL1 | |
| SCHEMBL9109795 | 0.92 | ATM (0.50) | ATMCNR1CNR2MMEALDH1A1 | |
| SCHEMBL9108330 | 0.84 | ATM (0.43) | ATMCNR1CNR2MMEGAA | |
| SCHEMBL9106115 | 0.84 | ATM (0.43) | ATMCNR1CNR2MMEGAA | |
| SCHEMBL6508319 | 0.81 | CNR1 (0.43) | ATMCNR1CNR2MMEOGFRL1 | |
| SCHEMBL992855 | 0.71 | POLB (0.35) | GAAPOLBACE | |
| SCHEMBL28153658 | 0.70 | ATM (0.57) | ATMMMEALDH1A1GAAACE | |
| SCHEMBL3718206 | 0.69 | CNR2 (0.40) | CNR1CNR2ALDH1A1ACE | |
| SCHEMBL5080962 | 0.69 | POLB (0.38) | CNR1CNR2ALDH1A1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ATM 4704/4885CNR1 2/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.